Accounting for functional loss in Alzheimer's disease and dementia with Lewy bodies: Beyond cognition

Hamilton, Joanne M.; Salmon, David P.; Raman, Rema; Hansen, Lawrence A.; Masliah, Eliezer; Peavy, Guerry M.; Galasko, Douglas

doi:10.1016/j.jalz.2013.04.003

Cited by 19 publications

(15 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Not surprising, worse cognition predicted worse functioning. These results are aligned with findings from other studies . In fact, cognition has been identified as a primary predictor as well as a moderator variable when examining different types of functioning .…”

Section: Discussionsupporting

confidence: 90%

“…These results are aligned with findings from other studies. 9,14,37 In fact, cognition has been identified as a primary predictor as well as a moderator variable when examining different types of functioning. 9,38 Compromised attention, frontal dysfunction (ie, initiation, perseveration, and conceptualization), poor construction abilities, and impaired memory, all cognitive abilities measured in this study, would explain worsening abilities to accomplish many instrumental activities of daily living (IADLs).…”

Section: Compromised Cognitionmentioning

confidence: 99%

See 1 more Smart Citation

Associations among Braak stage, Parkinsonian gait, cognition, and functional status in autopsy‐confirmed dementia with Lewy bodies

Mayo

Peavy

2019

Int J Geriat Psychiatry

Self Cite

View full text Add to dashboard Cite

Objective Compromised functional abilities in older adults with dementia with Lewy bodies (DLB) represent a significant burden to families and frequently lead to institutionalization. Contributing factors to this compromise are poorly understood. Methods Using data collected at a first study visit, multiple regression modeling was used to examine the associations between Braak staged Alzheimer disease (AD) pathology, Apolipoprotein E (ApoE) status, Parkinsonian gait, cognition, and functional status from a cohort of 102 cases with an autopsy‐confirmed diagnosis of dementia stemming from combined Lewy body and AD pathology. Results On average, 60% of functional activities were compromised per case. Worse functional status was associated with older age at first study visit, compromised cognitive status, and Parkinsonian gait after controlling for gender, mental status, and other covariates. Worse cognitive status predicted worse functional status in both the low and high Braak groups. Conclusions Older persons with DLB presenting with moderately compromised cognition and Parkinsonian gait should be expected to have impaired functional abilities. Providing these patients with supportive environments may help them to remain independent for longer periods of time.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Compromised Cognitionmentioning

confidence: 99%

Associations among Braak stage, Parkinsonian gait, cognition, and functional status in autopsy‐confirmed dementia with Lewy bodies

Mayo

Peavy

2019

Int J Geriat Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Research on the diagnosis and management of dementia with Lewy bodies (DLB) has increased greatly in the past decade [1][2][3][4][5][6][7][8][9][10][11]. Currently it is thought that DLB represents about 10-15% of all dementia cases [12].…”

Section: Introductionmentioning

confidence: 99%

Paired Studies Comparing Clinical Profiles of Lewy Body Dementia with Alzheimer’s and Parkinson’s Diseases

Scharre

Chang

Nagaraja

et al. 2016

JAD

View full text Add to dashboard Cite

Abstract. Limited data compares clinical profiles of Lewy Body Dementia (LBD) with Alzheimer's disease (AD) andParkinson's disease (PD). Twenty-one mildly demented ambulatory LBD subjects were individually matched by MMSE score with 21 AD subjects and by UPDRS motor score with 21 PD subjects. Matched by age, gender, education, and race, pairs were compared using cognitive, functional, behavioral, and motor measures. LBD group performed worse than PD on axial motor, gait, and balance measures. AD had more amnesia and orientation impairments, but less executive and visuospatial deficits than LBD subjects. LBD group had more sleepiness, cognitive/behavioral fluctuations, hallucinations, and sleep apnea than AD or PD. Axial motor, gait, and balance disturbances correlated with executive, visuospatial, and global cognition deficits. LBD is differentiated from AD and PD by retrieval memory, visuospatial, and executive deficits; axial motor, gait and balance impairments; sleepiness, cognitive/behavioral fluctuations, hallucinations, and sleep apnea.

show abstract

“…Alzheimer's disease is a progressive neurodegenerative disorder which damages the brain and is characterized by the progressive decline in memory and other cognitive abilities [1]. Alzheimer's Disease (AD) causes sensory and cognitive impairments that in later stages of the disease render the coverage of everyday life demands extremely difficult [2].…”

Section: Introductionmentioning

confidence: 99%

The effect of Risperidone, Sertraline as monotherapy and in combination with Cholinesterase inhibitors on cognitive functioning due to Alzheimer’s Disease: A randomized clinical trial

Melissari-Tzanakaki¹,

Benioudakis²,

Botonaki³

et al. 2017

Alzheimers Dement Cogn Neurol

View full text Add to dashboard Cite

Alzheimer's disease is a progressive neurodegenerative disorder which is characterized by the progressive decline in memory and other cognitive abilities. Behavioral and personality changes can also be present. Depression is also a neuropsychiatric aspect of Alzheimer's disease. Objective:The aim of this study is to compare the effect of risperidone as monotherapy in patients with behavioral problems, sertraline as monotherapy in patients with depression and with the combination of cholinesterase inhibitors on cognitive functioning due to Alzheimer's Disease. Methods and Participants:The study comprised 78 participants diagnosed with AD, all over fifty years of age. The participants were split into 4 groups: groups A and B had everyday behavioral problems, while groups C and D had co-morbid depression. Group A was treated with risperidone 1mg daily, group B with risperidone and cholinesterase inhibitors, Group C was treated with sertraline, and group D with sertraline and cholinesterase inhibitors. Baseline assessment of groups A and B was performed using the instrumental activities of daily living (IADL) Scale, Physical Self-Maintenance Scale (PSMS), Mini-Mental State Examination Scale (MMSE), while a follow-up assessment after three and six months was only with MMSE. Groups C and D were assessed with MMSE and the Montgomery-Asberg Depression Rating Scale for baseline assessment and follow-up after 12 months.Results: It was found that group A (treated with risperidone only) showed a statistically significant improvement in MMSE scores with respect to the baseline assessment after 6 months, An improvement not seen in group B (treated with risperidone and cholinesterase inhibitors). Groups C and D did not show any significant improvement in scores on either assessment scale. Conclusion:Risperidone used as monotherapy displayed a positive effect on cognitive function due to Alzheimer's.

show abstract

Accounting for functional loss in Alzheimer's disease and dementia with Lewy bodies: Beyond cognition

Cited by 19 publications

References 48 publications

Associations among Braak stage, Parkinsonian gait, cognition, and functional status in autopsy‐confirmed dementia with Lewy bodies

Associations among Braak stage, Parkinsonian gait, cognition, and functional status in autopsy‐confirmed dementia with Lewy bodies

Paired Studies Comparing Clinical Profiles of Lewy Body Dementia with Alzheimer’s and Parkinson’s Diseases

The effect of Risperidone, Sertraline as monotherapy and in combination with Cholinesterase inhibitors on cognitive functioning due to Alzheimer’s Disease: A randomized clinical trial

Contact Info

Product

Resources

About